Breakthrough pain and its treatment

critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo, Massimo Mammucari, Augusto Tommaso Caraceni

Research output: Contribution to journalArticle

Abstract

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

Original languageEnglish
Pages (from-to)961-968
Number of pages8
JournalSupportive Care in Cancer
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Breakthrough Pain
Fentanyl
Pain
Therapeutics
Opioid Analgesics
Epidemiology
Pharmacology
Cancer Pain
Surveys and Questionnaires
Pharmaceutical Preparations

Keywords

  • Breakthrough pain
  • Fentanyl
  • Morphine
  • Opioids

ASJC Scopus subject areas

  • Oncology

Cite this

Breakthrough pain and its treatment : critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. / Mercadante, Sebastiano; Marchetti, Paolo; Cuomo, Arturo; Mammucari, Massimo; Caraceni, Augusto Tommaso.

In: Supportive Care in Cancer, Vol. 24, No. 2, 01.02.2016, p. 961-968.

Research output: Contribution to journalArticle

@article{28b00028f41d46d8bab233496b9419a1,
title = "Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group",
abstract = "Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.",
keywords = "Breakthrough pain, Fentanyl, Morphine, Opioids",
author = "Sebastiano Mercadante and Paolo Marchetti and Arturo Cuomo and Massimo Mammucari and Caraceni, {Augusto Tommaso}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s00520-015-2951-y",
language = "English",
volume = "24",
pages = "961--968",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Breakthrough pain and its treatment

T2 - critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

AU - Mercadante, Sebastiano

AU - Marchetti, Paolo

AU - Cuomo, Arturo

AU - Mammucari, Massimo

AU - Caraceni, Augusto Tommaso

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

AB - Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

KW - Breakthrough pain

KW - Fentanyl

KW - Morphine

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=84952874686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952874686&partnerID=8YFLogxK

U2 - 10.1007/s00520-015-2951-y

DO - 10.1007/s00520-015-2951-y

M3 - Article

VL - 24

SP - 961

EP - 968

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -